PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth of 0.49% while GNPX is zero. Bruce Berkowitz would see if minimal improvements could expand further.
56.85%
Positive EBIT growth while GNPX is negative. John Neff might see a substantial edge in operational management.
54.90%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
56.85%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
56.86%
EPS growth above 1.5x GNPX's 34.62%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
56.86%
Diluted EPS growth above 1.5x GNPX's 34.62%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.00%
Share reduction while GNPX is at 80.76%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while GNPX is at 80.76%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
28.81%
OCF growth above 1.5x GNPX's 7.14%. David Dodd would confirm a clear edge in underlying cash generation.
28.81%
FCF growth above 1.5x GNPX's 7.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while GNPX stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.99%
10Y OCF/share CAGR in line with GNPX's 91.62%. Walter Schloss would see both as similarly efficient over the decade.
56.40%
5Y OCF/share CAGR at 50-75% of GNPX's 96.48%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-114.69%
Negative 3Y OCF/share CAGR while GNPX stands at 96.26%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
96.39%
Similar net income/share CAGR to GNPX's 99.56%. Walter Schloss would see parallel tailwinds or expansions for both firms.
45.76%
Below 50% of GNPX's 96.58%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
32.63%
Below 50% of GNPX's 96.48%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-96.80%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-86.34%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-81.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.00%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-9.98%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-36.64%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-70.64%
We cut SG&A while GNPX invests at 52.68%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.